Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- And β-adrenergic receptor antagonists in hemiparkinsonian rats

Pharmacology Biochemistry and Behavior

Volumn 100, Issue 3, 2012, Pages 607-615

  Barnum, Christopher J ^a   Bhide, Nirmal ^a   Lindenbach, David ^a   Surrena, Margaret A ^a   Goldenberg, Adam A ^a   Tignor, Stefanie ^a   Klioueva, Anna ^a   Walters, Hannah ^a   Bishop, Christopher ^a  

^a BINGHAMTON UNIVERSITY   (United States)

Author keywords

Alpha adrenergic; Beta adrenergic; Dyskinesia; L DOPA; Norepinephrine; Parkinson's disease

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESIPRAMINE; IDAZOXAN; LEVODOPA; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DENERVATION; DRUG EFFICACY; DYSKINESIA; HIPPOCAMPUS; MALE; NONHUMAN; NORADRENERGIC NERVE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC NEURONS; ANIMALS; BEHAVIOR, ANIMAL; CORPUS STRIATUM; DESIPRAMINE; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; HIPPOCAMPUS; IDAZOXAN; LEVODOPA; MALE; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SYMPATHECTOMY, CHEMICAL;

RATTUS;

EID: 83555178498     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2011.09.009     Document Type: Article

References (73)

1. A. Arai, M. Tomiyama, K. Kannari, T. Kimura, C. Suzuki, and M. Watanabe Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter Synapse 62 8 2008 632 635 (Pubitemid 351951301)
2. B. Arvin, E. Le Peillet, N. Dürmüller, A.G. Chapman, and B.S. Meldrum Electrolytic lesions of the locus coeruleus or 6-hydroxydopamine lesions of the medial forebrain bundle protect against excitotoxic damage in rat hippocampus Brain Res 579 2 1992 279 284
3. C.J. Barnum, K.L. Eskow, K. Dupre, P. Blandino, T. Deak, and C. Bishop Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta Neuroscience 156 1 2008 30 41
4. G. Bing, Y. Zhang, Y. Watanabe, B.S. McEwen, and E.A. Stone Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra Brain Res 668 1-2 1994 261 265
5. C. Bishop, D.M. Krolewski, K.L. Eskow, C.J. Barnum, K.B. Dupre, and T. Deak Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats J Neurosci Res 87 7 2009 1645 1658
6. K. Buck, and B. Ferger Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats Neuroscience 159 1 2009 16 20
7. K. Buck, and B. Ferger The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease Synapse 64 2 2010 117 126
8. K. Buck, P. Voehringer, and B. Ferger The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine- lesioned rats J Neurochem 112 2 2010 444 452
9. A.F. Carpentier, A.M. Bonnet, M. Vidailhet, and Y. Agid Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease Neurology 46 6 1996 1548 1551 (Pubitemid 26185769)
10. M.A. Cenci, and H. Lindgren Advances in understanding L-DOPA-induced dyskinesia Curr Opin Neurobiol 17 6 2007 655 671
11. M.A. Cenci, I.Q. Whishaw, and T. Schallert Animal models of neurological deficits: how relevant is the rat Nat Rev Neurosci 3 7 2002 574 579 (Pubitemid 135706667)
12. J. Chang, S. Wachtel, and U. Kang Biochemical and anatomical characterization of forepaw adjusting steps in rats models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions Neuroscience 88 2 1999 617 628 (Pubitemid 28480020)
13. W. Dauer, and S. Przedborski Parkinson's disease: mechanisms and models Neuron 39 2003 889 909 (Pubitemid 37130207)
14. A. Dekundy, M. Lundblad, W. Danysz, and M. Cenci Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model Behav Brain Res 179 2007 76 89 (Pubitemid 46441485)
15. E.F. Domino, L. Ni, F. Colpaert, and M. Marien Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys Receptors Channels 9 5 2003 335 338 (Pubitemid 37369346)
16. K. Eskow, V. Gupta, S. Alam, J. Park, and C. Bishop The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy Pharmacol Biochem Behav 87 2007 306 314 (Pubitemid 47101876)
17. F. Fornai, L. Bassi, M.T. Torracca, V. Scalori, and G.U. Corsini Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice Eur J Pharmacol 283 1-3 1995 99 102
18. F. Fornai, A.B. di Poggio, A. Pellegrini, S. Ruggieri, and A. Paparelli Noradrenaline in Parkinson's disease: from disease progression to current therapeutics Curr Med Chem 14 22 2007 2330 2334 (Pubitemid 47618041)
19. S.H. Fox, B. Henry, M.P. Hill, D. Peggs, A.R. Crossman, and J.M. Brotchie Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan Mov Disord 16 4 2001 642 650 (Pubitemid 36040843)
20. F. Fulceri, F. Biagioni, M. Ferrucci, G. Lazzeri, A. Bartalucci, and V. Galli Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons Brain Res 1135 1 2007 219 229 (Pubitemid 46176834)
21. A. Gobert, R. Billiras, L. Cistarelli, and M.J. Millan Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors J Neurosci Method 140 1-2 2004 141 152 (Pubitemid 39625862)
22. B. Gomez-Mancilla, and P.J. Bedard Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys Clin Neuropharmacol 16 5 1993 418 427 (Pubitemid 23292096)
23. R. Grondin, A. Hadj Tahar, V.D. Doan, P. Ladure, and P.J. Bedard Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys Naunyn Schmiedebergs Arch Pharmacol 361 2 2000 181 186 (Pubitemid 30062450)
24. A. Haapalinna, T. Leino, and E. Heinonen The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats Naunyn Schmiedebergs Arch Pharmacol 368 5 2003 342 351 (Pubitemid 37491493)
25. M. Hara, R. Fukui, E. Hieda, M. Kuroiwa, H.S. Bateup, and T. Kano Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons J Neurochem 113 4 2010 1046 1059
26. B. Henry, S.H. Fox, D. Peggs, A.R. Crossman, and J.M. Brotchie The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease Mov Disord 14 5 1999 744 753 (Pubitemid 29509616)
27. M. Holmberg, M. Scheinin, H. Kurose, and R. Miettinen Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry Neuroscience 93 4 1999 1323 1333 (Pubitemid 29397560)
28. O. Hornykiewicz, and S.J. Kish Biochemical pathophysiology of Parkinson's disease Adv Neurol 45 1987 19 34
29. Z.A. Hughes, and S.C. Stanford A partial noradrenergic lesion induced by DSP-4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo Psychopharmacology (Berl) 136 3 1998 299 303 (Pubitemid 28143180)
30. E.W. Johnson, B.B. Wolfe, and P.B. Molinoff Regulation of subtypes of beta-adrenergic receptors in rat brain following treatment with 6-hydroxydopamine J Neurosci 9 7 1989 2297 2305 (Pubitemid 19193562)
31. T.H. Johnston, S.H. Fox, M.J. Piggott, J.M. Savola, and J.M. Brotchie The alpha adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates Mov Disord 25 13 2010 2084 2093
32. B.E. Jones, and R.Y. Moore Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study Brain Res 127 1 1977 25 53
33. I.C. Kilpatrick, M.W. Jones, and O.T. Phillipson A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation J Neurochem 46 6 1986 1865 1876 (Pubitemid 16095494)
34. C.A. Kitt, and S.E. Brauth Telencephalic projections from midbrain and isthmal cell groups in the pigeon. I. Locus coeruleus and subcoeruleus J Comp Neurol 247 1 1986 69 91 (Pubitemid 16073286)
35. F. Lanau, M.T. Zenner, O. Civelli, and D.S. Hartman Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor J Neurochem 68 2 1997 804 812 (Pubitemid 27044746)
36. A.J. Lategan, M.R. Marien, and F.C. Colpaert Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis Brain Res 523 1 1990 134 138 (Pubitemid 20226592)
37. A.J. Lategan, M.R. Marien, and F.C. Colpaert Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study Life Sci 50 14 1992 995 999
38. D. Lindenbach, C.Y. Ostock, K.L. Eskow Jaunarajs, K.B. Dupre, C.J. Barnum, and N. Bhide Behavioral and cellular modulation of L-DOPA-induced dyskinesia by β-adrenoceptor receptor blockade in the 6-OHDA lesioned rat J Pharmacol Exp Ther 337 3 2011 755 765
39. O. Lindvall, and A. Bjorklund The organization of the ascending catecholamine neuron systems in the rat brain as revealed by the glyoxylic acid fluorescence method Acta Physiol Scand Suppl 412 1974 1 48
40. D. Lorton, J. Bartolome, T.A. Slotkin, and J.N. Davis Development of brain beta-adrenergic receptors after neonatal 6-hydroxydopamine treatment Brain Res Bull 21 4 1988 591 600 (Pubitemid 19272117)
41. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M. Cenci Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur J Neurosci 15 1 2002 120 132 (Pubitemid 35478015)
42. G. Luscombe, A. Clow, P. Jenner, and C.D. Marsden Antagonism by propranolol of central dopamine receptor stimulation is not related to beta-adrenergic blockade J Pharm Pharmacol 31 5 1979 355 356 (Pubitemid 9207610)
43. M. Marien, M. Briley, and F. Colpaert Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice Eur J Pharmacol 236 3 1993 487 489 (Pubitemid 23170392)
44. C. Marin, E. Aguilar, and M. Bonastre Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats J Neural Transm 115 8 2008 1133 1139
45. M. Mavridis, A.D. Degryse, A.J. Lategan, M.R. Marien, and F.C. Colpaert Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease Neuroscience 41 2-3 1991 507 523
46. R.L. McBride, and J. Sutin Projections of the locus coeruleus and adjacent pontine tegmentum in the cat J Comp Neurol 165 3 1976 265 284
47. P.J. McMillan, S.S. White, A. Franklin, J.L. Greenup, J.B. Leverenz, and M.A. Raskind Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease Brain Res 1373 2011 240 252
48. J. Meitzen, J.I. Luoma, C.M. Stern, and P.G. Mermelstein beta1-Adrenergic receptors activate two distinct signaling pathways in striatal neurons J Neurochem 116 6 2011 984 995
49. H. Narabayashi, T. Kondo, T. Nagatsu, A. Hayashi, and T. Suzuki DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism Adv Neurol 40 1984 497 502
50. H. Narabayashi, F. Yokochi, T. Ogawa, and T. Igakura Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease No To Shinkei 43 3 1991 263 268
51. A. Newman-Tancredi, V. Audinot-Bouchez, A. Gobert, and M.J. Millan Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors Eur J Pharmacol 319 2-3 1997 379 383 (Pubitemid 27056063)
52. A.P. Nicholas, V.A. Pieribone, and T. Hokfelt Cellular localization of messenger RNA for beta-1 and beta-2 adrenergic receptors in rat brain: an in situ hybridization study Neuroscience 56 4 1993 1023 1039 (Pubitemid 23308657)
53. K. Nishi, T. Kondo, and H. Narabayashi Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa Neurosci Lett 123 2 1991 244 247
54. J. Obeso, M. Rodriguez-Oroz, P. Chana, G. Lera, M. Rodriguez, and C. Olanow The evolution and origin of motor complications in Parkinson's disease Neurology 55 11 Suppl 4 2000 S13 S23
55. H. Oka, M. Yoshioka, K. Onouchi, M. Morita, S. Mochio, and M. Suzuki Characteristics of orthostatic hypotension in Parkinson's disease Brain 130 Pt 9 2007 2425 2432 (Pubitemid 47327636)
56. Paxinos G, Watson W. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego: Academic Press, p. 1-456.
57. V. Perez, V. Sosti, A. Rubio, M. Barbanoj, I. Gich, and J. Rodriguez-Alvarez Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats J Neural Transm 116 7 2009 867 874
58. B.N. Prichard, J.M. Cruickshank, and B.R. Graham Beta-adrenergic blocking drugs in the treatment of hypertension Blood Press 10 5-6 2001 366 386 (Pubitemid 34083360)
59. D. Putterman, A. Munhall, L. Kozell, J. Belknap, and S. Johnson Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease J Pharmacol Exp Ther 323 1 2007 277 284 (Pubitemid 47443278)
60. T.C. Rainbow, B. Parsons, and B.B. Wolfe Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain Proc Natl Acad Sci USA 81 5 1984 1585 1589 (Pubitemid 14174548)
61. O. Rascol, I. Arnulf, H. Peyro-Saint Paul, C. Brefel-Courbon, M. Vidailhet, and C. Thalamas Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease Mov Disord 16 4 2001 708 713 (Pubitemid 36040852)
62. K.S. Rommelfanger, and D. Weinshenker Norepinephrine: the redheaded stepchild of Parkinson's disease Biochem Pharmacol 74 2 2007 177 190 (Pubitemid 46890808)
63. K.S. Rommelfanger, G.L. Edwards, K.G. Freeman, L.C. Liles, G.W. Miller, and D. Weinshenker Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice Proc Natl Acad Sci USA 104 34 2007 13804 13809 (Pubitemid 350003401)
64. Santhera licenses novel dyskinesia therapy to Biovail. Nat Rev Drug Discov 2009;8(10):762
65. J.M. Savola, M. Hill, M. Engstrom, H. Merivuori, S. Wurster, and S.G. McGuire Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease Mov Disord 18 8 2003 872 883 (Pubitemid 37021161)
66. J. Srinivasan, and W. Schmidt Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats J Neural Transm 111 1 2003 13 26 (Pubitemid 38177814)
67. P. Szot, C. Miguelez, S.S. White, A. Franklin, C. Sikkema, and C.W. Wilkinson A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat Neuroscience 166 1 2010 279 291
68. S.M. Tejani-Butt, W.P. Pare, and J. Yang Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats Brain Res 649 1-2 1994 27 35 (Pubitemid 24197193)
69. C. Waeber, M. Rigo, G. Chinaglia, A. Probst, and J.M. Palacios Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease Synapse 8 4 1991 270 280
70. G.J. Wang, Y.S. Yao, and H.X. Wang Comparing effects of U50488H, prazosin and/or propranolol on cardiac hypertrophy induced by NE in rat Zhongguo Ying Yong Sheng Li Xue Za Zhi 26 1 2010 82 85
71. L. Yavich, R. Lappalainen, J. Sirvio, A. Haapalinna, and E. MacDonald Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum Eur J Pharmacol 339 2-3 1997 113 119 (Pubitemid 28021855)
72. L. Yavich, J. Sirvio, A. Haapalinna, A. Ylinen, and P.T. Mannisto Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum Eur J Pharmacol 462 1-3 2003 83 89 (Pubitemid 36183738)
73. C. Zarow, S.A. Lyness, J.A. Mortimer, and H.C. Chui Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases Arch Neurol 60 3 2003 337 341 (Pubitemid 36314358)